News - Circle Pharma

Background Publications on Macrocycles

Our Science

The Promise of Macrocycles

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut. labore et dolore magnam aliquam quaerat voluptatem.

CID-078, a First-in-Class Oral Macrocycle CyclinA/B-RxL Inhibitor, Demonstrates Anti-Tumor Activity in E2F-driven Cancers

October 23, 2024

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

October 23, 2024

Circle Pharma announces first patients dosed in Phase 1 clinical trial of first-in-class oral Cyclin A/B RxL inhibitor
CID-078 for advanced solid tumors

October 15, 2024

Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment

October 9, 2024

Circle Pharma expands leadership team to drive the development of its pipeline of oral macrocycle therapies

September 16, 2024

Circle Pharma announces preclinical data poster presentation of CID-078, a first-and-only-in-class Cyclin A/B RxL inhibitor at the 2024 World Conference on Lung Cancer

September 9, 2024

Orally bioavailable Cyclin A/B RxL macrocycle has antitumor effect in SCLC and NSCLC cell line derived (CDX) and patient derived xenograft (PDX) models

September 9, 2024

Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies

September 3, 2024

Permeable macrocyclic peptide Cyclin A/B RxL inhibitors: synthetic development, SAR and in vivo target validation

August 22, 2024